Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Posts Increased Revenues, Narrowed Losses in Q2

NEW YORK, July 21 (GenomeWeb News) - Luminex said today that revenues for the second quarter of 2004 rose to $9.2 million from $5.6 million for the same period in 2003.

 

Meanwhile, net loss for the company in the second quarter dipped slightly to $1.1 million from $1.9 million in Q2 of 2003.

 

The company said that Q2 revenues consisted of $5.3 million from sales of 218 Luminex systems and $2.1 million from the sales of consumables. Year-to-date revenues have nearly doubled over last year, rising to $18.5 million in 2004 from $10.7 million for the corresponding period in 2003.

 

Luminex spent $987,000 on R&D in the second quarter of 2004 as compared to $881,000 for Q2 of 2003. As of June 30, the company had cash and cash equivalents on hand of $54 million.

 

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.